Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Eli Lilly and Company |
---|---|
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00036309 |
The purpose of this study is to determine if duloxetine is effective when compared to placebo in preventing recurrence of major depressive disorder in patients who have responded to open-label duloxetine treatment.
Condition | Intervention | Phase |
---|---|---|
Depressive Disorder |
Drug: Duloxetine Hydrochloride |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 4445, F1J-MC-HMBC |
Study First Received: | May 8, 2002 |
Last Updated: | July 18, 2006 |
ClinicalTrials.gov Identifier: | NCT00036309 |
Health Authority: | United States: Food and Drug Administration |
Major Depressive Disorder Diagnostic and Statistical Manual of Mental Disorders Fourth Edition-defined major depressive disorder without psychotic features |
Dopamine Depression Mental Disorders Mood Disorders Psychotic Disorders |
Depressive Disorder, Major Depressive Disorder Serotonin Duloxetine Behavioral Symptoms |
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Disease Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic Uptake Inhibitors Physiological Effects of Drugs Psychotropic Drugs |
Serotonin Uptake Inhibitors Pharmacologic Actions Pathologic Processes Serotonin Agents Therapeutic Uses Dopamine Agents Central Nervous System Agents Antidepressive Agents |